Evidence map›Paper›PMID 38544906›Full record

ArticleTherapeutic advances in chronic disease2024

Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.

Deborah A Marshall, Karen V MacDonald, Dina Kao, Charles N Bernstein, Gilaad G Kaplan, Humberto Jijon, Glen Hazlewood, Remo Panaccione, Yasmin Nasser, Maitreyi Raman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in chronic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Deborah A MarshallDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Room 3C58, Health Research Innovation Centre, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada.ORCID https://orcid.org/0000-0002-8467-8008
Karen V MacDonaldDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Dina KaoDivision of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Charles N BernsteinSection of Gastroenterology, and University of Manitoba IBD Clinical and Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Gilaad G KaplanDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Humberto JijonDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Glen HazlewoodDivision of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Remo PanaccioneDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Yasmin NasserDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Maitreyi RamanDivision of Gastroenterology and Hepatology, Department of Medicine and Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Paul MoayyediFarncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada.
University of Calgary · CAPopulation Health Research Institute · CAUniversity of Alberta · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fecal microbiota transplantation (FMT) is a promising treatment for active ulcerative colitis (UC). Understanding patient preferences can identify treatment features that may impact treatment decisions, improve shared decision-making, and contribute to patient-centered care, which is especially important in the context of novel treatments like FMT. Objectives: We aimed to quantify preferences for active UC treatments, specifically FMT and biologics, and identify patient characteristics associated with different preference patterns. Design: This is a cross-sectional survey study. Methods: We administered a discrete choice experiment (DCE) survey to elicit preferences in a sample of Canadian adults with UC. DCE data were analyzed using a main-effects mixed logit model and used to predict uptake of hypothetical scenarios reflecting alternative combinations of treatment features. Latent class modeling identified heterogeneity in patient preference patterns. Results: Participants' ( Conclusion: We identified characteristics of UC patients who are more likely to be interested in FMT using preference elicitation methods. Patient-centered care can be enhanced by knowing which patients are more likely to be interested in FMT, potentially improving satisfaction with and adherence to treatments for active UC to maximize the effectiveness of treatment while considering heterogeneity in patient preferences.

Indexed as

fecal microbiota transplantationpatient preferencesulcerative colitis

Identifiers

PMID38544906
PMCPMC10966996
OpenAlexW4393360017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.